A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations

Inclusion Criteria:

• The participant has a documented diagnosis of asthma for at least 1 year accordingto the 2022 GINA guidelines.

• The participant has a documented history of at least 1 severe clinical asthmaexacerbation (CAE) ending within the past 12 month.

• The participant is using any prescribed inhaled asthma controller medication (at astable dose for 1 month prior to the screening visit).

• If female, the participant is currently not pregnant, breastfeeding, or attemptingto become pregnant (for at least 30 days before the screening visit and throughoutthe duration of the study), or is of nonchildbearing potential

NOTE- Additional criteria apply, please contact the investigator for more information.

Exclusion Criteria:

• The participant has life-threatening asthma defined as any history of significantasthma episode(s) requiring intubation associated with hypercapnia, respiratoryarrest, hypoxic seizures, or asthma related syncopal episode(s) within 5 yearsbefore screening.

• The participant has a suspected bacterial or viral infection (other than CoronavirusDisease [COVID-19]) of the upper or lower respiratory tract, sinus, or middle earthat has not resolved at least 2 weeks before the screening period.

• Participants with a confirmed infection with COVID-19 within 6 weeks prior to thescreening visit, or with residual COVID-19 symptoms ("long COVID-19").

• The participant has had a clinical asthma exacerbation (CAE) requiring systemiccorticosteroids within 30 days before screening, or any hospitalization for asthmawithin 2 months before screening.

• The participant is a current smoker and/or has a history of ≥10 pack years historyof smoking. A current smoker is defined as any participant who has used any form oftobacco product (including oral) within the past 6 months.

• The participant has significantly abused alcohol and/or illicit prohibited drugswithin the previous 24 months.

• The participant has participated as a randomized participant in any investigationaldrug study within 30 days.

• The participant has been hospitalized for psychiatric disorder or attempted suicidewithin 1 year of screening.

NOTE- Additional criteria apply, please contact the investigator for more information